Loading…
Exagen Inc. is projected to rise to $8.51 by 2027, a +70% move from its current price of $5.01. XGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.77 | $5.01 | $5.28 | +0.10% |
| May 30 | $4.67 | $5.02 | $5.39 | +0.19% |
| May 31 | $4.60 | $5.02 | $5.49 | +0.29% |
| Jun 1 | $4.54 | $5.03 | $5.57 | +0.39% |
| Jun 2 | $4.49 | $5.03 | $5.64 | +0.49% |
| Jun 3 | $4.45 | $5.04 | $5.71 | +0.58% |
| Jun 4 | $4.41 | $5.04 | $5.77 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.41 | $5.04 | $5.77 | +0.68% |
| Week 2 | $4.20 | $5.08 | $6.14 | +1.37% |
| Week 3 | $4.05 | $5.11 | $6.45 | +2.06% |
| Week 4 | $3.93 | $5.15 | $6.74 | +2.76% |
| Week 5 | $3.84 | $5.18 | $7.00 | +3.46% |
| Week 6 | $3.75 | $5.22 | $7.26 | +4.17% |
| Week 7 | $3.68 | $5.25 | $7.50 | +4.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Exagen Inc. designs, develops, and commercializes testing products under the AVISE brand in the United States. The company enables healthcare providers to diagnose, prognosis, and monitor complex rheumatic and autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Its lead testing product is AVISE CTD, and the AVISE portfolio includes AVISE Lupus platform, AVISE APS, AVISE Vasculitis AAV, AVISE Anti-Histone, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE SLE Monitor, AVISE MTX, and AVISE HCQ. Exagen was incorporated in 2002 and is headquartered in Vista, California; it was renamed Exagen Inc. in January 2019.
The company has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers.
Exagen Inc. (XGN) is a healthcare company with a current price of $5.01 and a market cap of $121.04M, ranked 4095.
The stock’s price action is currently framed by a 30-day trading range of $3.58 to $7.00, with a current price of $5.01. The near-term forecast shows a 2026 average price of $5.01, a low of $2.65, and a high of $8.73, with a neutral stance.
Longer-term projections lift the average price meaningfully toward 2030, 2040, and 2050, signaling notable upside potential through multi-year horizons, culminating in an average of $51.85 by 2050.
In the period beyond 2026, the forecast series indicates bullish momentum with 2027 average $8.51 and progressively higher averages through 2050, including a 2050 average of $51.85 and a 2050 max of $119.24.
A major floor 62.0% below — a decisive break under it would weaken the trend.
The nearest floor, 46.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 31.0% above — clearing it would confirm fresh momentum.
Key XGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.40 | Buy | $4.48 | Buy |
| MA 10 | $4.02 | Buy | $4.14 | Buy |
| MA 20 | $3.59 | Buy | $3.77 | Buy |
| MA 50 | $3.19 | Buy | $3.54 | Buy |
| MA 100 | $3.64 | Buy | $4.11 | Buy |
| MA 200 | $6.50 | Sell | $5.05 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.02 | Sell |
| Stoch RSI (14) | 99.96 | Sell |
| CCI (20) | 188.72 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 69.83 | Buy |
| Bollinger %B (20,2) | 1.09 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.13 | Buy |
| Awesome (5,34) | 1.08 | Buy |
| Ultimate (7,14,28) | 82.93 | Sell |
| Momentum (10) | 1.30 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 4.80 | Buy |
| ADX (14) | 25.33 | Buy |
| ATR (14) | 0.20 | Info |
The 14-day RSI stands at 80, indicating strong near-term momentum. The sentiment is BULLISH in the forecast framework.
The stock’s moving-average backdrop shows SMA50 at $3.19 and SMA200 at $6.50, with the current price at $5.01. This places the price above the 50-day average but below the 200-day average, suggesting resistance around the longer-term level. Support is noted at $2.68, while resistance is marked at $5.01.
The 30-day price range spans $3.58 to $7.00, highlighting notable near-term volatility (annualized volatility listed at 100%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.65 | $5.01 | $8.73 | 0% | Neutral | |
| $6.18 | $8.51 | $12.65 | +70% | Bullish | |
| $6.37 | $9.26 | $14.61 | +85% | Bullish | |
| $6.99 | $10.68 | $17.63 | +113% | Bullish | |
| $6.00 | $9.57 | $16.42 | +91% | Bullish | |
| $5.74 | $9.54 | $16.92 | +91% | Bullish | |
| $7.75 | $13.38 | $24.43 | +167% | Bullish | |
| $9.41 | $16.87 | $31.62 | +237% | Bullish | |
| $9.75 | $18.14 | $34.83 | +262% | Bullish | |
| $9.28 | $17.89 | $35.12 | +257% | Bullish | |
| $13.83 | $30.74 | $66.10 | +514% | Bullish | |
| $23.33 | $51.85 | $119.24 | +935% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.65 | $5.01 | $6.03 | +0.00% |
| June 2026 | $4.56 | $5.46 | $6.76 | +8.99% |
| July 2026 | $4.50 | $5.47 | $6.95 | +0.26% |
| August 2026 | $4.74 | $5.83 | $7.54 | +6.58% |
| September 2026 | $5.12 | $6.37 | $8.36 | +9.24% |
| October 2026 | $5.05 | $6.34 | $8.44 | -0.45% |
| November 2026 | $4.84 | $6.13 | $8.25 | -3.33% |
| December 2026 | $5.02 | $6.42 | $8.73 | +4.62% |
Click any year to see its month-by-month XGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, XGN could reach as high as $8.73, with a base case around $5.01 and support toward $2.65 — roughly 0% from $5.01. Price action looks broadly range-bound.
Expect XGN to range from $6.18 to $12.65 through 2027. The $8.51 average target implies a +70% move from current prices. That is up +70% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The XGN price prediction for 2028 points to an average of $9.26 (low $6.37, high $14.61) — a potential gain of +85% on today's $5.01. Momentum favours further upside here.
In 2029, XGN is projected to trade between $6.99 and $17.63, averaging $10.68 — a potential gain of +113% from today's $5.01. That is up +15% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Exagen Inc.'s 2030 outlook centres on $9.57, within a $6.00 to $16.42 range. That is -10% versus the projected 2029 average. That marks a +91% change versus current levels. Momentum favours further upside here.
By 2031, XGN could reach as high as $16.92, with a base case around $9.54 and support toward $5.74 — roughly +91% from $5.01. Buyers look set to stay in control over this stretch.
Expect XGN to range from $7.75 to $24.43 through 2032. The $13.38 average target implies a +167% move from current prices. That is up +40% on the projected 2031 average. Momentum favours further upside here.
The XGN price prediction for 2033 points to an average of $16.87 (low $9.41, high $31.62) — a potential gain of +237% on today's $5.01. Buyers look set to stay in control over this stretch.
In 2034, XGN is projected to trade between $9.75 and $34.83, averaging $18.14 — a potential gain of +262% from today's $5.01. That is up +8% on the projected 2033 average. Momentum favours further upside here.
Exagen Inc.'s 2035 outlook centres on $17.89, within a $9.28 to $35.12 range. That is -1% versus the projected 2034 average. That marks a +257% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, XGN could reach as high as $66.10, with a base case around $30.74 and support toward $13.83 — roughly +514% from $5.01. Momentum favours further upside here.
Expect XGN to range from $23.33 to $119.24 through 2050. The $51.85 average target implies a +935% move from current prices. That is up +69% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in XGN today (≈ 199.600798 XGN) could be worth
$10,348.32
+$9,348.32 (+935%) by 2050 · US Dollar
Based on the average projected XGN price of $51.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XGNwould be worth at today's price.
$1,000 invested in XGN on May 27, 2025 (≈ 146.842879 XGN) would be worth
$735.68
-$264.32 (-26.4%) today · 0.74× · US Dollar
Based on a XGN entry price of $6.81 vs. today's $5.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.83 | $1,308.09 | +30.8% |
| 1 month ago | $2.74 | $1,828.47 | +82.8% |
| 3 months ago | $3.8 | $1,318.42 | +31.8% |
| 6 months ago | $7.9 | $634.18 | -36.6% |
| 1 year ago | $6.81 | $735.68 | -26.4% |
| All time (5.0y) ago | $13.76 | $364.1 | -63.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XGN forecast.
Our base-case forecast reaches $10.00 around 2029.
Implied market cap at $10.00: $241.6M
The multi-year path envisions substantial upside across the 2027–2050 window. For 2027 the avg price is $8.51 with a 69.8% ROI, followed by 2028 at $9.26 (84.9%), and 2029 at $10.68 (113.1%). By 2030 the avg is projected at $9.57 with a 91.1% ROI, continuing a bullish arc beyond 2030.
The forecast shows even larger gains later in the decade with 2032 avg $13.38 (167.2% ROI) and 2033 avg $16.87 (236.7%), rising to 2034 avg $18.14 (262.1%) and 2035 avg $17.89 (257.2%). By 2040 the average climbs to $30.74 (513.6% ROI) and by 2050 to $51.85 (934.8% ROI), with a 2050 max of $119.24.
These figures represent estimates, not guarantees, and reflect potential upside under the given assumptions. They should be interpreted with awareness of inherent investment risks and uncertainty.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $9.57, a minimum of $6.00, and a maximum of $16.42, with a projected ROI of 91.1% and a bullish sentiment.
The outlook is bullish from 2027 onward, with 2027 avg $8.51 (ROI 69.8%), 2028 avg $9.26 (ROI 84.9%), 2029 avg $10.68 (ROI 113.1%), 2032 avg $13.38 (ROI 167.2%), 2033 avg $16.87 (ROI 236.7%), 2040 avg $30.74 (ROI 513.6%), and 2050 avg $51.85 (ROI 934.8%). The 2026 forecast is neutral.
Yes. The 2050 forecast shows an average of $51.85 and a maximum of $119.24, indicating potential to surpass $50 on the upside.
Current price is $5.01 and market cap is $121.04M.
The 30-day range is $3.58 to $7.00.
Exagen Inc. Community Discussion
0Share your Exagen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.